Multi-parameter exploration of HIV-1 virus-like particles as neutralizing antibody immunogens in guinea pigs, rabbits and macaques

Virology

Volumn 456-457, Issue 1, 2014, Pages 55-69

  Tong, Tommy ^a   Crooks, Ema T ^a   Osawa, Keiko ^a   Robinson, James E ^b   Barnes, Mary ^c   Apetrei, Cristian ^c,d   Binley, James M ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b TULANE UNIVERSITY   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antibody; Env; Gp120; Gp41; HIV; Neutralization; Vaccine; VLPs

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 120; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; CROSS REACTION; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RABBIT; SPECIES COMPARISON; SPECIES DIFFERENCE; VACCINATION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

ANTIBODY; ENV; GP120; GP41; HIV; NEUTRALIZATION; VACCINE; VLPS;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; FEMALE; GUINEA PIGS; HIV ANTIBODIES; HIV-1; MACACA MULATTA; MALE; MODELS, ANIMAL; RABBITS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84897093858     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.03.015     Document Type: Article

References (98)

1. Abdel-Motal U.M., Wang S., Awad A., Lu S., Wigglesworth K., Galili U. Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes. Vaccine 2010, 28:1758-1765.
2. Agrawal N., Leaman D.P., Rowcliffe E., Kinkead H., Nohria R., Akagi J., Bauer K., Du S.X., Whalen R.G., Burton D.R., Zwick M.B. Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1). PLoS One 2011, 6:e21339.
3. Alving C.R. Antibodies to lipids and liposomes: immunology and safety. J. Liposome Res. 2006, 16:157-166.
4. Alving C.R. 4E10 and 2F5 monoclonal antibodies: binding specificities to phospholipids, tolerance, and clinical safety issues. AIDS 2008, 22:649-651.
5. Binley J.M., Ban Y.E., Crooks E.T., Eggink D., Osawa K., Schief W.R., Sanders R.W. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J. Virol. 2010, 84:5637-5655.
6. Binley J.M., Cayanan C.S., Wiley C., Schulke N., Olson W.C., Burton D.R. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J. Virol. 2003, 77:5678-5684.
7. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., Decker J.M., Wycuff D., Harris L., Hawkins N., Wood B., Nathe C., Richman D., Tomaras G.D., Bibollet-Ruche F., Robinson J.E., Morris L., Shaw G.M., Montefiori D.C., Mascola J.R. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 2008, 82:11651-11668.
8. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., Kajumo F., Anselma D.J., Maddon P.J., Olson W.C., Moore J.P. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 2000, 74:627-643.
9. Binley J.M., Sanders R.W., Master A., Cayanan C.S., Wiley C.L., Schiffner L., Travis B., Kuhmann S., Burton D.R., Hu S.L., Olson W.C., Moore J.P. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 2002, 76:2606-2616.
10. Blish C.A., Nguyen M.A., Overbaugh J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med. 2008, 5:e9.
11. Bomsel M., Tudor D., Drillet A.S., Alfsen A., Ganor Y., Roger M.G., Mouz N., Amacker M., Chalifour A., Diomede L., Devillier G., Cong Z., Wei Q., Gao H., Qin C., Yang G.B., Zurbriggen R., Lopalco L., Fleury S. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269-280.
12. Brown B.K., Karasavvas N., Beck Z., Matyas G.R., Birx D.L., Polonis V.R., Alving C.R. Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J. Virol. 2007, 81:2087-2091.
13. Buonaguro L., Visciano M.L., Tornesello M.L., Tagliamonte M., Biryahwaho B., Buonaguro F.M. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J. Virol. 2005, 79:7059-7067.
14. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
15. Chen X., Rock M.T., Hammonds J., Tartaglia J., Shintani A., Currier J., Slike B., Crowe J.E., Marovich M., Spearman P. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. J. Virol. 2005, 79:5537-5547.
16. Crooks E.T., Jiang P., Franti M., Wong S., Zwick M.B., Hoxie J.A., Robinson J.E., Moore P.L., Binley J.M. Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 2008, 377:364-378.
17. Crooks E.T., Moore P.L., Franti M., Cayanan C.S., Zhu P., Jiang P., de Vries R.P., Wiley C., Zharkikh I., Schulke N., Roux K.H., Montefiori D.C., Burton D.R., Binley J.M. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 2007, 366:245-262.
18. Crooks E.T., Moore P.L., Richman D., Robinson J., Crooks J.A., Franti M., Schulke N., Binley J.M. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum. Antib. 2005, 14:101-113.
19. Crooks E.T., Tong T., Osawa K., Binley J.M. Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J. Virol. 2011, 85:5825-5839.
20. Denisova G., Stern B., Raviv D., Zwickel J., Smorodinsky N.I., Gershoni J.M. Humoral immune response to immunocomplexed HIV envelope glycoprotein 120. AIDS Res. Hum. Retrovir. 1996, 12:901-909.
21. Dennison S.M., Sutherland L.L., Jaeger F.H., Anasti K.M., Parks R., Stewart S., Bowman C., Xia S.M., Zhang R., Shen X., Scearce R.M., Ofek G., Yang Y., Kwong P.D., Santra S., Liao H.X., Tomaras G., Letvin N.L., Chen B., Alam S.M., Haynes B.F. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One 2011, 6:e27824.
22. SF162 and heterologous HIV-1 infection. J. Virol. 2006, 80:8745-8762.
23. Doan L.X., Li M., Chen C., Yao Q. Virus-like particles as HIV-1 vaccines. Rev. Med. Virol. 2005, 15:75-88.
24. Earl P.L., Doms R.W., Moss B. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 1990, 87:648-652.
25. Emini E.A., Koff W.C. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Science 2004, 304:1913-1914.
26. Evans D.T., Bricker J.E., Sanford H.B., Lang S., Carville A., Richardson B.A., Piatak M., Lifson J.D., Mansfield K.G., Desrosiers R.C. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. J. Virol. 2005, 79:7707-7720.
27. Forthal D.N., Gilbert P.B., Landucci G., Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 2007, 178:6596-6603.
28. Garrone P., Fluckiger A.C., Mangeot P.E., Gauthier E., Dupeyrot-Lacas P., Mancip J., Cangialosi A., Du Chene I., LeGrand R., Mangeot I., Lavillette D., Bellier B., Cosset F.L., Tangy F., Klatzmann D., Dalba C. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 2011, 3. (94ra71).
29. Grovit-Ferbas K., Hsu J.F., Ferbas J., Gudeman V., Chen I.S. Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1. J. Virol. 2000, 74:5802-5809.
30. Grundner C., Mirzabekov T., Sodroski J., Wyatt R. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J. Virol. 2002, 76:3511-3521.
31. Hammonds J., Chen X., Ding L., Fouts T., De Vico A.,Megede J., Barnett S., Spearman P. Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core. Virology 2003, 314:636-649.
32. Hammonds J., Chen X., Fouts T., DeVico A., Montefiori D., Spearman P. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J. Virol. 2005, 79:14804-14814.
33. Hammonds J., Chen X., Zhang X., Lee F., Spearman P. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine 2007, 25:8036-8048.
34. Hicar M.D., Chen X., Briney B., Hammonds J., Wang J.J., Kalams S., Spearman P.W., Crowe J.E. Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. J. Acquir. Immune Defic. Syndr. 2010, 54:223-235.
35. Hioe C.E., Visciano M.L., Kumar R., Liu J., Mack E.A., Simon R.E., Levy D.N., Tuen M. The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. Vaccine 2009, 28:352-360.
36. Hoot S., McGuire A.T., Cohen K.W., Strong R.K., Hangartner L., Klein F., Diskin R., Scheid J.F., Sather D.N., Burton D.R., Stamatatos L. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 2013, 9:e1003106.
37. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S., Imamichi H., Bailer R.T., Chakrabarti B., Sharma S.K., Alam S.M., Wang T., Yang Y., Zhang B., Migueles S.A., Wyatt R., Haynes B.F., Kwong P.D., Mascola J.R., Connors M. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491:406-412.
38. Jobe O., Peachman K.K., Matyas G.R., Asher L.V., Alving C.R., Rao M. An anti-phosphoinositide-specific monoclonal antibody that neutralizes HIV-1 infection of human monocyte-derived macrophages. Virology 2012, 430:110-119.
39. Joyner A.S., Willis J.R., Crowe J.E., Aiken C. Maturation-induced cloaking of neutralization epitopes on HIV-1 particles. PLoS Pathog. 2011, 7:e1002234.
40. Kamdem Toukam D., Tenbusch M., Stang A., Temchura V., Storcksdieck Genannt Bonsmann M., Grewe B., Koch S., Meyerhans A., Nchinda G., Kaptue L., Uberla K. Targeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus. PLoS One 2012, 7:e38068.
41. Kanekiyo M., Wei C.J., Yassine H.M., McTamney P.M., Boyington J.C., Whittle J.R., Rao S.S., Kong W.P., Wang L., Nabel G.J. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013, 499(7456):102-106.
42. Kang Y.K., Andjelic S., Binley J.M., Crooks E.T., Franti M., Iyer S.P., Donovan G.P., Dey A.K., Zhu P., Roux K.H., Durso R.J., Parsons T.F., Maddon P.J., Moore J.P., Olson W.C. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 2009, 27:5120-5132.
43. Keller M.A., Arora Y. Inhibition of the anti-V3 loop response to a recombinant gp120SF2 vaccine by preexisting monoclonal antibody. AIDS Res. Hum. Retrovir. 1999, 15:855-860.
44. Klasse P.J., Sanders R.W., Cerutti A., Moore J.P. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?. AIDS Res. Hum. Retrovir. 2012, 28:1-15.
45. Kong L., Lee J.H., Doores K.J., Murin C.D., Julien J.P., McBride R., Liu Y., Marozsan A., Cupo A., Klasse P.J., Hoffenberg S., Caulfield M., King C.R., Hua Y., Le K.M., Khayat R., Deller M.C., Clayton T., Tien H., Feizi T., Sanders R.W., Paulson J.C., Moore J.P., Stanfield R.L., Burton D.R., Ward A.B., Wilson I.A. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 2013, 20:796-803.
46. Kulkarni P.S., Manjunath K., Agarkhedkar S. Safety and immunogenicity of an adjuvanted whole virion, inactivated A (H1N1) 2009 influenza vaccine in young and elderly adults, and children. Vaccine 2012, 31:20-22. Group of S.I.I.I.I.V.S.
47. Kushnir N., Streatfield S.J., Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012, 31:58-83.
48. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37:412-425.
49. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franti M., Binley J., Vivona V., Grundner C., Huang C.C., Venturi M., Petropoulos C.J., Wrin T., Dimitrov D.S., Robinson J., Kwong P.D., Wyatt R.T., Sodroski J., Burton D.R. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 2003, 77:10557-10565.
50. Leaman D.P., Kinkead H., Zwick M.B. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J. Virol. 2010, 84:3382-3395.
51. Li M., Gao F., Mascola J., Stamatatos L., Polonis V.R., Koutsoukos M., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B., Montefiori D. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79:10108-10125.
52. Li Y., Svehla K., Mathy N.L., Voss G., Mascola J.R., Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J. Virol. 2006, 80:1414-1426.
53. Liao H.X., Alam S.M., Mascola J.R., Robinson J., Ma B., Montefiori D.C., Rhein M., Sutherland L.L., Scearce R., Haynes B.F. Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. J. Virol. 2004, 78:5270-5278.
54. Lifson J.D., Rossio J.L., Piatak M., Bess J., Chertova E., Schneider D.K., Coalter V.J., Poore B., Kiser R.F., Imming R.J., Scarzello A.J., Henderson L.E., Alvord W.G., Hirsch V.M., Benveniste R.E., Arthur L.O. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res. Hum. Retrovir. 2004, 20:772-787.
55. Lorizate M., Sachsenheimer T., Glass B., Habermann A., Gerl M.J., Krausslich H.G., Brugger B. Comparative lipidomics analysis of HIV-1 particles and their producer cell membrane in different cell lines. Cell. Microbiol. 2013, 15:292-304.
56. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
57. Matyas G.R., Wieczorek L., Bansal D., Chenine A.L., Sanders-Buell E., Tovanabutra S., Kim J.H., Polonis V., Alving C.R. Inhibition of HIV-1 infection of peripheral blood mononuclear cells by a monoclonal antibody that binds to phosphoinositides and induces secretion of beta-chemokines. Biochem. Biophys. Res. Commun. 2010, 402:808-812.
58. McBurney S.P., Young K.R., Ross T.M. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007, 358:334-346.
59. McCoy L.E., Weiss R.A. Neutralizing antibodies to HIV-1 induced by immunization. J. Exp. Med. 2013, 210:209-223.
60. McGuire A.T., Hoot S., Dreyer A.M., Lippy A., Stuart A., Cohen K.W., Jardine J., Menis S., Scheid J.F., West A.P., Schief W.R., Stamatatos L. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 2013, 210:655-663.
61. McKenna P.M., Aye P.P., Dietzschold B., Montefiori D.C., Martin L.N., Marx P.A., Pomerantz R.J., Lackner A., Schnell M.J. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. J. Virol. 2004, 78:13455-13459.
62. McKenna P.M., Pomerantz R.J., Dietzschold B., McGettigan J.P., Schnell M.J. Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. J. Virol. 2003, 77:12782-12794.
63. Montero M., Gulzar N., Klaric K.A., Donald J.E., Lepik C., Wu S., Tsai S., Julien J.P., Hessell A.J., Wang S., Lu S., Burton D.R., Pai E.F., Degrado W.F., Scott J.K. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J. Virol. 2012, 86:2930-2941.
64. Moody M.A., Liao H.X., Alam S.M., Scearce R.M., Plonk M.K., Kozink D.M., Drinker M.S., Zhang R., Xia S.M., Sutherland L.L., Tomaras G.D., Giles I.P., Kappes J.C., Ochsenbauer-Jambor C., Edmonds T.G., Soares M., Barbero G., Forthal D.N., Landucci G., Chang C., King S.W., Kavlie A., Denny T.N., Hwang K.K., Chen P.P., Thorpe P.E., Montefiori D.C., Haynes B.F. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J. Exp. Med. 2010, 207:763-776.
65. Moore J.P., Sattentau Q.J., Wyatt R., Sodroski J. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 1994, 68:469-484.
66. Moore J.P., Thali M., Jameson B.A., Vignaux F., Lewis G.K., Poon S.W., Charles M., Fung M.S., Sun B., Durda P.J., et al. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J. Virol. 1993, 67:4785-4796.
67. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., Corcoran P., Zwick M.B., Franti M., Morris L., Roux K.H., Burton D.R., Binley J.M. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 2006, 80:2515-2528.
68. Nyambi P.N., Gorny M.K., Bastiani L., van der Groen G., Williams C., Zolla-Pazner S. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J. Virol. 1998, 72:9384-9391.
69. O'Rourke S.M., Schweighardt B., Scott W.G., Wrin T., Fonseca D.P., Sinangil F., Berman P.W. Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. J. Virol. 2009, 83:7728-7738.
70. Ota T., Doyle-Cooper C., Cooper A.B., Huber M., Falkowska E., Doores K.J., Hangartner L., Le K., Sok D., Jardine J., Lifson J., Wu X., Mascola J.R., Poignard P., Binley J.M., Chakrabarti B.K., Schief W.R., Wyatt R.T., Burton D.R., Nemazee D. Anti-HIV B Cell lines as candidate vaccine biosensors. J. Immunol. 2012, 189:4816-4824.
71. Pan R., Sampson J.M., Chen Y., Vaine M., Wang S., Lu S., Kong X.P. Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can mimic the antigen-binding modes of antibodies derived from HIV-1-infected humans. J. Virol. 2013, 87:10221-10231.
72. Pastori C., Tudor D., Diomede L., Drillet A.S., Jegerlehner A., Rohn T.A., Bomsel M., Lopalco L. Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. Virology 2012, 431:1-11.
73. Pinheiro A., Lanning D., Alves P.C., Mage R.G., Knight K.L., van der Loo W., Esteves P.J. Molecular bases of genetic diversity and evolution of the immunoglobulin heavy chain variable region (IGHV) gene locus in leporids. Immunogenetics 2011, 63:397-408.
74. Poon B., Safrit J.T., McClure H., Kitchen C., Hsu J.F., Gudeman V., Petropoulos C., Wrin T., Chen I.S., Grovit-Ferbas K. Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. J. Virol. 2005, 79:4927-4935.
75. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev. Vaccines 2010, 9:1149-1176.
76. Rossio J.L., Esser M.T., Suryanarayana K., Schneider D.K., Bess J.W., Vasquez G.M., Wiltrout T.A., Chertova E., Grimes M.K., Sattentau Q., Arthur L.O., Henderson L.E., Lifson J.D. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 1998, 72:7992-8001.
77. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., Kwong P.D., Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 2002, 76:7293-7305.
78. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of a1-->2 mannose residues on the outer face of gp120. J. Virol. 2002, 76:7306-7321.
79. Schiffner T., Sattentau Q.J., Dorrell L. Development of prophylactic vaccines against HIV-1. Retrovirology 2013, 10:72.
80. Shen X., Dennison S.M., Liu P., Gao F., Jaeger F., Montefiori D.C., Verkoczy L., Haynes B.F., Alam S.M., Tomaras G.D. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc. Natl. Acad. Sci. USA 2010, 107:5972-5977.
81. Sims P.J., Wiedmer T. Unraveling the mysteries of phospholipid scrambling. Thromb. Haemost. 2001, 86:266-275.
82. Soares M.M., King S.W., Thorpe P.E. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 2008, 14:1357-1362.
83. Sun N.C., Ho D.D., Sun C.R., Liou R.S., Gordon W., Fung M.S., Li X.L., Ting R.C., Lee T.H., Chang N.T., et al. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J. Virol. 1989, 63:3579-3585.
84. Tomaras G.D., Binley J.M., Gray E.S., Crooks E.T., Osawa K., Moore P.L., Tumba N., Tong T., Shen X., Yates N.L., Decker J., Wibmer C.K., Gao F., Alam S.M., Easterbrook P., Abdool Karim S., Kamanga G., Crump J.A., Cohen M., Shaw G.M., Mascola J.R., Haynes B.F., Montefiori D.C., Morris L. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 2011, 85:11502-11519.
85. Tong T., Crooks E.T., Osawa K., Binley J.M. HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J. Virol. 2012, 86:3574-3587.
86. Tong T., Osawa K., Robinson J.E., Crooks E.T., Binley J.M. Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility compared to soluble Gp120. J. Virol. 2013, 87:9233-9249.
87. Vaine M., Wang S., Crooks E.T., Jiang P., Montefiori D.C., Binley J., Lu S. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J. Virol. 2008, 82:7369-7378.
88. van Gils M.J., Sanders R.W. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology 2013, 435:46-56.
89. van Montfort T., Nabatov A.A., Geijtenbeek T.B., Pollakis G., Paxton W.A. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes. J. Immunol. 2007, 178:3177-3185.
90. VanCott T.C., Mascola J.R., Kaminski R.W., Kalyanaraman V., Hallberg P.L., Burnett P.R., Ulrich J.T., Rechtman D.J., Birx D.L. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 1997, 71:4319-4330.
91. Visciano M.L., Diomede L., Tagliamonte M., Tornesello M.L., Asti V., Bomsel M., Buonaguro F.M., Lopalco L., Buonaguro L. Generation of HIV-1 virus-like particles expressing different HIV-1 glycoproteins. Vaccine 2011, 29:4903-4912.
92. Visciano M.L., Tuen M., Gorny M.K., Hioe C.E. in vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology 2008, 372:409-420.
93. Vzorov A.N., Lea-Fox D., Compans R.W. Immunogenicity of full length and truncated SIV envelope proteins. Viral Immunol. 1999, 12:205-215.
94. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., Wang S.K., Ramos A., Chan-Hui P.Y., Moyle M., Mitcham J.L., Hammond P.W., Olsen O.A., Phung P., Fling S., Wong C.H., Phogat S., Wrin T., Simek M.D., Koff W.C., Wilson I.A., Burton D.R., Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
95. Xiang S.-H., Doka N., Choudhary R.K., Sodroski J., Robinson J.E. Characterization of CD4-induced epitopes on the HIV-1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retrovir. 2002, 18:1207-1217.
96. Yang L., Song Y., Li X., Huang X., Liu J., Ding H., Zhu P., Zhou P. HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component. J. Virol. 2012, 86:7662-7676.
97. Zhou Z.R., Wang M.L., Deng F., Li T.X., Hu Z.H., Wang H.L. Production of CCHF virus-like particle by a baculovirus-insect cell expression system. Virol. Sin. 2011, 26:338-346.
98. Zwick M.B., Saphire E.O., Burton D.R. gp41: HIV's shy protein. Nat. Med. 2004, 10:133-134.